Kenneth R Chapman1, Eric D Bateman2, Hungta Chen3, Hulin Hu3, Robert Fogel3, Donald Banerji3. 1. Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Ontario, Canada. 2. Department of Medicine, University of Cape Town, South Africa. 3. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Abstract
Background: QVA149 is a dual bronchodilator combining the long-acting β2-agonist(LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, for maintenance treatment of COPD. This post hoc analysis evaluated the improvements in lung function, dyspnea, and health status in subgroups of patients based on prior medication use, disease severities, baseline cough score, and baseline rescue medication use, achieved with QVA149 compared with placebo and other active comparators in 2 phase III clinical studies. Methods: In both the SHINE (NCT01202188) and ILLUMINATE (NCT01315249) studies, symptomatic patients aged ≥40 years with moderate-to-severe COPD were randomized to once-daily QVA149 (110/50 µg), indacaterol (150 µg), glycopyrronium (50 µg), tiotropium (18 μg), or placebo (2:2:2:2:1) and once-daily QVA149 (110/50 µg) or twice-daily salmeterol/fluticasone ([SFC]; 50/500 µg), respectively for 26 weeks. Here, we present the improvements in lung function, transition dyspnea index (TDI) and St. George's Respiratory Questionnaire (SGRQ) total score by prior medication use and COPD disease severity separately from both studies. Results:In total, 2144 and 523 patients were randomized in the SHINE and ILLUMINATE studies; 89.1% and 82.6%, respectively, completed the study. QVA149 showed significant improvements in lung function compared with placebo (SHINE study) and SFC (ILLUMINATE study) regardless of prior medication, disease severity, baseline cough score, and rescue medication use. TDI and SGRQ total scores were also improved with QVA149 compared with placebo and SFC in most of the analyzed subgroups. Conclusion:QVA149 showed improvements in lung function, dyspnea, and health status in both moderate and severe COPD patients independent of previous medication use and baseline cough score.
RCT Entities:
Background: QVA149 is a dual bronchodilator combining the long-acting β2-agonist(LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, for maintenance treatment of COPD. This post hoc analysis evaluated the improvements in lung function, dyspnea, and health status in subgroups of patients based on prior medication use, disease severities, baseline cough score, and baseline rescue medication use, achieved with QVA149 compared with placebo and other active comparators in 2 phase III clinical studies. Methods: In both the SHINE (NCT01202188) and ILLUMINATE (NCT01315249) studies, symptomatic patients aged ≥40 years with moderate-to-severe COPD were randomized to once-daily QVA149 (110/50 µg), indacaterol (150 µg), glycopyrronium (50 µg), tiotropium (18 μg), or placebo (2:2:2:2:1) and once-daily QVA149 (110/50 µg) or twice-daily salmeterol/fluticasone ([SFC]; 50/500 µg), respectively for 26 weeks. Here, we present the improvements in lung function, transition dyspnea index (TDI) and St. George's Respiratory Questionnaire (SGRQ) total score by prior medication use and COPD disease severity separately from both studies. Results: In total, 2144 and 523 patients were randomized in the SHINE and ILLUMINATE studies; 89.1% and 82.6%, respectively, completed the study. QVA149 showed significant improvements in lung function compared with placebo (SHINE study) and SFC (ILLUMINATE study) regardless of prior medication, disease severity, baseline cough score, and rescue medication use. TDI and SGRQ total scores were also improved with QVA149 compared with placebo and SFC in most of the analyzed subgroups. Conclusion:QVA149 showed improvements in lung function, dyspnea, and health status in both moderate and severe COPDpatients independent of previous medication use and baseline cough score.
Authors: Donald A Mahler; Anthony D'Urzo; Eric D Bateman; Serir A Ozkan; Tracy White; Clare Peckitt; Cheryl Lassen; Benjamin Kramer Journal: Thorax Date: 2012-04-27 Impact factor: 9.139
Authors: Claus Vogelmeier; Peter Kardos; Sergio Harari; Steven J M Gans; Stephan Stenglein; Jackie Thirlwell Journal: Respir Med Date: 2008-09-19 Impact factor: 3.415
Authors: Kenneth R Chapman; Stephen I Rennard; Angeli Dogra; Roger Owen; Cheryl Lassen; Benjamin Kramer Journal: Chest Date: 2011-02-24 Impact factor: 9.410
Authors: J A van Noord; J-L Aumann; E Janssens; J J Smeets; J Zaagsma; A Mueller; P J G Cornelissen Journal: Respir Med Date: 2010-03-29 Impact factor: 3.415
Authors: Marc Decramer; Ronald Dahl; Oliver Kornmann; Stephanie Korn; David Lawrence; Danny McBryan Journal: Respir Med Date: 2012-12-06 Impact factor: 3.415
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Anthony D'Urzo; Gary T Ferguson; Jan A van Noord; Kazuto Hirata; Carmen Martin; Rachael Horton; Yimeng Lu; Donald Banerji; Tim Overend Journal: Respir Res Date: 2011-12-07
Authors: Edward Kerwin; Jacques Hébert; Nicola Gallagher; Carmen Martin; Tim Overend; Vijay K T Alagappan; Yimeng Lu; Donald Banerji Journal: Eur Respir J Date: 2012-07-26 Impact factor: 16.671
Authors: Charlie Strange; Valery Walker; Michael DePietro; Junliang Tong; Jonathan Kurlander; Maureen Carlyle; Lauren A Millette; Eric Wittbrodt Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-06-28